IntelliXR Launches Its Platform for Eye and Brain Biomarkers

IntelliXR brings together the Ocunur headset, an SDK and API, and IntelliMDM, giving research and product teams one platform to capture, manage, and study eye and brain biomarkers at clinical scale.

United States, October 17, 2026 -- IntelliXR, the platform for eye and brain biomarkers from CitrusBits, today announced its official launch. The platform unites the Ocunur headset, an SDK and API, and IntelliMDM fleet management, so teams developing diagnostic, monitoring, and research applications can start from a single medical-grade foundation. The launch follows IntelliXR's soft launch at the Ophthalmology Futures European Forum in London in September, where the platform was presented to clinicians, investors, and industry leaders by Gaurav Malik.

Eye movements, pupil responses, and visual function are emerging as measurable signals of neurological and ophthalmic health. Capturing them reliably requires precise hardware, consistent software, and data handling that meets clinical standards. IntelliXR brings these together in three layers. The Ocunur headset captures the raw signal through binocular eye tracking, up to 3,000 nits of display brightness, and a dedicated patient response controller. The SDK and API provide one integration point for eye tracking, pupillometry, stimulus presentation, perimetry, and privacy controls. IntelliMDM manages headsets across sites, handling security, configuration, and over-the-air updates. Regulatory groundwork is already in place across ISO 13485, ISO 27001, HIPAA, and FDA readiness.

The platform is already proven in clinical use. RadiusXR delivers FDA-cleared, head-mounted visual field testing on the IntelliXR stack, with a 0.94 correlation to the clinical gold standard in the NOVA Trial and now supports more than 10,000 users across 2,000 clinics. RadiusXR was also recognized as a CES 2023 Honoree.

IntelliXR serves researchers studying eye movements and visual function, solution builders developing diagnostic and monitoring applications, pharma and biotech teams running studies with eye-based endpoints, CROs managing multi-site trials, and device makers adding eye and brain measurement to their products.

"The science of eye and brain biomarkers is moving quickly, but capturing those signals consistently across devices, sites, and studies has held many teams back," said Gaurav Malik, Chief Commercial Officer at CitrusBits. "IntelliXR gives them a medical-grade foundation from day one, so the next diagnostic or research tool can reach patients in months rather than years."

About IntelliXR

IntelliXR is the platform for eye and brain biomarkers, uniting the Ocunur headset, an SDK and API, and IntelliMDM in one medical-grade platform. Developed by CitrusBits, which has 18 years of experience in healthcare technology, IntelliXR serves researchers, solution builders, pharma and biotech teams, CROs, and device makers across ophthalmology, neurology, and adjacent clinical fields, with a mission to serve 1 million patients over the next five years.

IntelliXR works with partners and industry organizations across XR, telecom, and healthcare, including VRARA, T-Mobile, AgeTech, and HLTH.

Contact Info:
Name: Usman Malik
Email: Send Email
Organization: IntelliXR
Phone: (925) 452-6012
Website: http://intellixr.ai

Release ID: 89206233

Should you identify any discrepancies, concerns, or inaccuracies in the content provided in this press release or require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team is committed to addressing your concerns within 8 hours by taking necessary actions to resolve identified issues diligently or guiding you through the necessary steps for removal. Our dedication lies in providing accurate and reliable information.